What is idiopathic pulmonary fibrosis (IPF)? What’s it like living with it? And what treatments are currently available?

AdAlta (ASX:1AD) managing director and CEO Dr Tim Oldham joins the Stockhead TV studio to investigate these questions and more.

“There are half a million patients living under this death sentence of IPF around the world today. It is classed as a rare disease, but it is a large disease,” Oldham explained.

“We’re taking a whole new approach to treating fibrosis. There have been many attempts to improve on the existing market of drugs. Unfortunately, many of those have failed.”

Stockhead’s Sarah Hughan speaks with Tim Oldham to learn more about IPF and what AdAlta’s doing in the fight against it with lead i-body drug candidate, AD-214.

 

This video was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice.

Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in